GKB Ophthalmics financials

·Pharma & HealthChart ›

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast closeFY23Mar 2023
30.5—
0.10.1
11.211.2
41.6—
27.727.7
−1.1−1.1
−4.0%−4.0%
−3.6−3.6
−2.9−2.9
−10.4%−10.4%
−₹5.72−₹5.72
−1.1−1.1
−0.8−0.8
−2.0−2.0
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GKB₹60.50

GKB Ophthalmics Limited

· Pharma & Health
₹ CrorePeersFABTECHLAXMIDENTLTARSONSFISCHERMcap ₹30.5 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
Current
last close
Market Capitalization—30.5
- Cash, Equiv & ST Investments0.10.1
+ Total Debt11.211.2
Enterprise Value—41.6
Revenue27.727.7
EBITDA-1.1-1.1
Margin %-3.95-3.95
EBIT-3.6-3.6
Net Income-2.9-2.9
Margin %-10.39-10.39
EPS, Adj (current shares)-5.72-5.72
Cash from Operations-1.1-1.1
Capital Expenditures-0.8-0.8
Free Cash Flow-2.0-2.0
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY23 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.

GKB Ophthalmics financials and key ratios

Figures from the company's filings with NSE

In FY23 its consolidated net loss was ₹2.9 crore on revenue of ₹27.7 crore. Its debt-to-equity ratio was 0.41 on 31 March 2023.

Latest balance sheet
31 March 2023

GKB Ophthalmics at a glance · consolidated

Debt to equity
0.41net debt ₹10.8 Cr
Net worth
₹27.5 Cr31 March 2023
Free cash flow (FY23)
−₹2 Cr
EPS (FY23)
−₹5.72

Questions

Is GKB Ophthalmics debt free?

No. GKB Ophthalmics had borrowings of ₹11.2 crore on 31 March 2023 (consolidated balance sheet), a debt-to-equity ratio of 0.41. Its cash and current investments were ₹41 lakh, so its net debt was ₹10.8 crore.

What is the GKB Ophthalmics debt to equity ratio?

GKB Ophthalmics' debt-to-equity ratio was 0.41 on 31 March 2023: borrowings of ₹11.2 crore against total equity of ₹27.5 crore.

What is the GKB Ophthalmics book value per share?

GKB Ophthalmics' book value per share was ₹54.63 on 31 March 2023: shareholders' equity of ₹27.5 crore divided by the 50.37 lakh shares in issue.

What is the GKB Ophthalmics net worth?

GKB Ophthalmics' net worth — shareholders' equity in its consolidated balance sheet — was ₹27.5 crore on 31 March 2023.

What is the GKB Ophthalmics EPS?

GKB Ophthalmics' basic earnings per share (EPS) were −₹5.72 in FY23.

What is the GKB Ophthalmics free cash flow?

In FY23, GKB Ophthalmics generated ₹1.1 crore of cash from operations and spent ₹81 lakh on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of −₹2 crore.

What is the GKB Ophthalmics revenue and profit in FY23?

In FY23 (April 2022–March 2023), GKB Ophthalmics' consolidated net loss was ₹2.9 crore, on revenue from operations of ₹27.7 crore.

Where do these GKB Ophthalmics figures come from?

From GKB Ophthalmics' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.